“These results are really exciting. This could be a new front in the fight against MS.”
Researchers at Oregon Health & Science University have discovered that an antioxidant designed by scientists more than a dozen years ago to fight damage within human cells significantly helps symptoms in mice that have a multiple sclerosis-like disease.
The antioxidant — called MitoQ — has shown some promise in fighting neurodegenerative diseases. But this is the first time it has been shown to significantly reverse an MS-like disease in an animal.
The discovery could lead to an entirely new way to treat multiple sclerosis, which affects more than 2.3 million people worldwide.
Multiple sclerosis occurs when the body’s immune system attacks the myelin, or the protective sheath, surrounding nerve fibers of the central nervous system. Some underlying nerve fibers are destroyed. Resulting symptoms can include blurred vision and blindness, loss of balance, slurred speech, tremors, numbness and problems with memory and concentration.
The antioxidant research was published in the December edition of Biochimica et Biophysica Acta Molecular Basis of Disease. The research team was led by P. Hemachandra Reddy, Ph.D., an associate scientist in the Division of Neuroscience at OHSU’s Oregon National Primate Research Center.
To conduct their study, the researchers induced mice to contract a disease called experimental autoimmune encephalomyelitis, or EAE, which is very similar to MS in humans. They separated mice into four groups: a group with EAE only; a group that was given the EAE, then treated with the MitoQ; a third group that was given the MitoQ first, then given the EAE; and a fourth “control” group of mice without EAE and without any other treatment.
After 14 days, the EAE mice that had been treated with the MitoQ exhibited reduced inflammatory markers and increased neuronal activity in the spinal cord — an affected brain region in MS — that showed their EAE symptoms were being improved by the treatment. The mice also showed reduced loss of axons, or nerve fibers and reduced neurological disabilities associated with the EAE. The mice that had been pre-treated with the MitoQ showed the least problems. The mice that had been treated with MitoQ after EAE also showed many fewer problems than mice who were just induced to get the EAE and then given no treatment.
“The MitoQ also significantly reduced inflammation of the neurons and reduced demyelination,” Reddy said. “These results are really exciting. This could be a new front in the fight against MS.”
Even if the treatment continues to show promise, testing in humans would be years away. The next steps for Reddy’s team will be to understand the mechanisms of MitoQ neuroprotection in different regions of the brain, and how MitoQ protects mitochondria within the brain cells of the EAE mice. Mitochondria, components within all human cells, convert energy into forms that are usable by the cell.
There is a built-in advantage with MitoQ. Unlike many new drugs, MitoQ has been tested for safety in numerous clinical trails with humans. Since its development in the late 1990s, researchers have tested MitoQ’s ability to decrease oxidative damage in mitochondria.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- Smoking and Epstein–Barr virus infection in multiple sclerosis developmenton July 3, 2020 at 2:23 am
It is unclear whether smoking interacts with different aspects of Epstein–Barr virus (EBV) infection with regard to multiple sclerosis (MS) risk. We aimed to investigate whether smoking acts ...
- Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severityon July 2, 2020 at 2:26 am
Neurofilament light chain (NfL) has been demonstrated to correlate with multiple sclerosis disease severity as well as treatment response. Nevertheless, additional serum biomarkers are still needed to ...
- PROTXX and University of Alberta Announce Remote Personalized Healthcare Collaboration for Patients with Multiple Sclerosison June 30, 2020 at 5:02 am
PROTXX and University of Alberta Announce Remote Personalized Healthcare Collaboration for Patients with Multiple Sclerosis ...
- Primary Progressive Multiple Sclerosis Treatment Market 2020 Analysis report with Cross-Channel, Opportunities, Upturn Growth by 2026on June 29, 2020 at 3:20 am
The report provides rational insights along with historical and forecast data to aid in better understanding of ...
- Managing Multiple Sclerosis Relapseson June 26, 2020 at 12:10 pm
Sponsored Content by Zeposia MS is a disease in which the immune system attacks the protective myelin sheath that covers the nerves, creating damaging lesions that make it harder for signals to ...
- Multiple Sclerosis Drugs Market 2020 Top Manufacturers, Industry Share, Size, Regional Analysis, Types and Applications and Forecasts to 2025on June 26, 2020 at 4:54 am
Final Report will add the analysis of the impact of COVID-19 on this industry” Global “Multiple Sclerosis Drugs ...
- BRIEF-Geneuro Enrolls First Patient In Temelimab Phase 2 Multiple Sclerosis Trialon June 24, 2020 at 10:45 pm
GENEURO ENROLLS FIRST PATIENT IN TEMELIMAB PHASE 2 MULTIPLE SCLEROSIS TRIAL IN COLLABORATION WITH THE KAROLINSKA INSTITUTET’S ACADEMIC SPECIALIST CENTER (ASC) * GENEURO SA - ONE-YEAR SINGLE CENTER ...
- GeNeuro enrolls first patient in temelimab Phase 2 multiple sclerosis trial in collaboration with the Karolinska Institutet’s Academic Specialist Center (ASC)on June 24, 2020 at 10:30 pm
Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving th ...
- New MyMSTeam Resource Center Educates People Living With Multiple Sclerosis On The Importance of Treatment and Adherenceon June 24, 2020 at 9:30 am
Today, MyHealthTeams and EMD Serono, through their MS-LINK initiative, announced the launch of the Treatment and Adherence Resource Center within MyMSTeam, the social network for (MS). The ...
- Dosing underway in Sanofi’s late-stage SAR442168 trial in relapsing multiple sclerosison June 23, 2020 at 5:03 am
Phase 3 clinical trial of partner Principia Biopharma's (NASDAQ:PRNB) SAR442168 in patients with relapsing multiple sclerosis.Upon dosing, ...
via Bing News